Oculis Holding AG is a cash-burning biotechnology company below the minimum market cap threshold for investment, with 3 of 4 recent earnings misses and revenue declining 27%, though analysts project more than 229% upside from current levels based on the pipeline option value.
Thesis pillars
- Analyst Implied Pipeline Upside↓Deteriorating
- Cash Burn Quality Concerns→Stable
- Earnings Miss Pattern→Stable
- +1 more pillar — see the Why tab for full reasoning
Oculis Holding AG (OCS) Stock Analysis
Oversold Bounce setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.56: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Elevated put/call ratio: 2.00; Below-average business quality; Negative price momentum.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach... Read more
Sell if holding. Engine safety override at $10.56: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Elevated put/call ratio: 2.00; Below-average business quality; Negative price momentum. Chart setup: Oversold RSI 9, near Bollinger lower, volume surge. Score 4.9/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-09-14Recent Developments — Oculis Holding AG
Latest news
- NEWS Oculis Doses First PIONEER-1 Patient As Privosegtor Advances Into Registrational Testing For Optic Neuritis With FDA SPA — benzinga Aug 24, 2026 positive
- NEWS JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $20 — benzinga Aug 14, 2026 neutral
- NEWS Oculis Acquires Accure's Privosegtor And ACT-02 Assets In Deal Worth $3.8M Upfront Cash And Up To 2,050,000 Shares — benzinga Aug 10, 2026 positive
- NEWS Oculis Holding Q2 EPS $(0.20) Beats $(0.48) Estimate, Sales $392.150K Beat $260.000K Estimate — benzinga Aug 7, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Oculis Holding, Maintains $26 Price Target — benzinga Aug 5, 2026 positive
Generated 2026-09-14T06:07:01Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.56: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10. Specifically: Elevated put/call ratio: 2.00; Below-average business quality; Negative price momentum. Chart setup: Oversold RSI 9, near Bollinger lower, volume surge. Prior stop was $10.19. Score 4.9/10, moderate confidence.
Take-profit target: $13.43 (+27.2% upside). Prior stop was $10.19. Stop-loss: $10.19.
DATA_ISSUE: analyst_target_implausible (raw $35.77 vs price $10.56 — ratio 3.4×). Rejected, falling back to technical TP.; Quality below floor (1.9 < 4.0).
Oculis Holding AG trades at a P/E of N/A (forward -5.2). TrendMatrix value score: 5.0/10. Verdict: Sell.
15 analysts cover OCS with a consensus score of 4.4/5. Average price target: $36.
What does Oculis Holding AG do?Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic,...
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.